Donanemab In Medicare: Quick Reversal Of Alzheimer’s Coverage Limits Doubtful, Lilly Says

Lilly execs caution that even if FDA approves donanemab in 2023, no uptake of any significance is expected until 2024 and beyond. An accelerated approval would essentially preclude Medicare reimbursement, and a CMS policy change or more persuasive trial data could take some time.